Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D00298)
Name
Ganciclovir
Synonyms    Click to Show/Hide the Synonyms of This API
82410-32-0; Cytovene; Gancyclovir; Vitrasert; Zirgan; RS-21592; Ganciclovirum; Cymevene; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1H-purin-6(9H)-one; BW-759U; Virgan; BW 759U; 2'-NDG; 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine; UNII-P9G3CKZ4P5; 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine; MFCD00870588; 9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE; CHEBI:465284; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one; 9-((1,3-Dihydroxy-2-propoxy)methyl)guanine; Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-; Hydroxyacyclovir; P9G3CKZ4P5; 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one; MLS000028481; 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one; Ganciclovir, 98%; NCGC00015471-02; SMR000058324; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-1H-purin-6-one; Biolf 62; Ganciclovirum [Latin]; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol; CAS-82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one; 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one; 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone; DSSTox_CID_21032; DSSTox_RID_79613; DSSTox_GSID_41032; 2'-Nor-2'-deoxyguanosine; BIOLF-62; 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine; Citovirax; Cymevan; Cymeven; BW-B 759U; 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol; DRG-0018; 2-amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-1,9-dihydro-6H-purin-6-one; Vitrasert (TN); BW 759; Cytovene (TN); CCRIS 9212; HSDB 6512; SR-01000075894; GCV & MSL; Ganciclovir (JAN/USP/INN); 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-1H-purin-6-one; Ganciclovir,(S); 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one; BW-795; MB3795; Prestwick_1068; ST-605; Zirgan (TN); GCV & 1110U81; Ganciclovir [USAN:USP:INN:BAN:JAN]; Opera_ID_284; 2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one; Prestwick0_000839; Prestwick1_000839; Prestwick2_000839; Prestwick3_000839; Lopac-G-2536; CHEMBL182; EC 627-054-3; G 2536; SCHEMBL3033; Lopac0_000539; BSPBio_000797; MLS001077349; BIDD:GT0783; SPBio_002718; BPBio1_000877; ZINC1505; DTXSID8041032; methyl)-1H-purin-6(9H)-one; SCHEMBL14491348; BDBM85707; HMS1570H19; HMS2090K08; HMS2097H19; HMS2235C21; HMS3259B13; HMS3261L19; HMS3371H01; HMS3604L19; HMS3655M18; HMS3714H19; Pharmakon1600-01502362; ACT03317; BCP12705; NSC_3454; Tox21_110160; Tox21_500539; ANW-47031; BBL029078; BDBM50237614; NSC759656; PDSP1_000816; PDSP2_000803; SBB066292; STK801910; STL514515; 2-amino-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-3H-purin-6-one; AKOS004119898; AKOS026749928; AKOS037492029; Tox21_110160_1; Valganciclovir hydrochloride impurity a; AC-8069; CCG-204629; CS-2014; DB01004; Ganciclovir, >=99% (HPLC), powder; KS-1065; LP00539; MCULE-9512761592; NC00647; NE60398; NSC-759656; SDCCGSBI-0050522.P002; 2-Amino-1,9-dihydro-9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6H-purin-6-one; 2-Amino-9-(((1,3-dihydroxypropan-2-yl)oxy)methyl)-6,9-dihydro-1H-purin-6-one; SMP2_000038; NCGC00015471-01; NCGC00015471-03; NCGC00015471-04; NCGC00015471-05; NCGC00015471-06; NCGC00015471-08; NCGC00015471-16; NCGC00093928-01; NCGC00093928-02; NCGC00168567-01; NCGC00188980-01; NCGC00261224-01; 9-(1,3-dihydroxy-2propoxymethyl)guanine; AK-76645; HY-13637; SY027981; 9-(1,3-dihydroxy-2-propoxymethyl)guanine; AB0012496; CAS_82410-32-0; 2-amino-9-((1,3-dihydroxypropan-2-yloxy); 9-(1,3-dihydroxy-2-propoxymethyl)-guanine; EU-0100539; FT-0611007; FT-0668948; SW197135-3; EN300-49857; A11645; C07019; D00333; J10127; 40034-EP2377510A1; Ganciclovir 100 microg/mL in Acetonitrile:Water; 410G320; 9-[[(1,3-Dihydroxy-2-propyl)oxy]methyl]guanine; A840322; Ganciclovir, Antibiotic for Culture Media Use Only; Q417640; SR-01000721941; Q-201148; SR-01000075894-1; SR-01000075894-4; SR-01000721941-3; Z1259084907; Ganciclovir, European Pharmacopoeia (EP) Reference Standard; 2-[(2-amino-6-hydroxy-9H-purin-9-yl)methoxy]propane-1,3-diol; 2-azanyl-9-[1,3-bis(oxidanyl)propan-2-yloxymethyl]-3H-purin-6-one; Ganciclovir, United States Pharmacopeia (USP) Reference Standard; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}hydropurin-6-one; Ganciclovir, Pharmaceutical Secondary Standard; Certified Reference Material; 2-amino-9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}-1,9-dihydro-6H-purin-6-one; Ganciclovir, 1.0 mg/mL (1% 1M HCl in Methanol), certified reference material
Clinical Status
Approved
Disease Indication Cytomegalovirus infection ICD-11: 1D82 [1]
PubChem CID
135398740
Formula
C9H13N5O4
Canonical SMILES
C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N
InChI
1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17)
InChIKey
IRSCQMHQWWYFCW-UHFFFAOYSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=135398740"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 255.23 Topological Polar Surface Area 135
XlogP -2.5 Complexity 346
Heavy Atom Count 18 Rotatable Bond Count 5
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 6
Full List of Drug Formulations (DFMs) Containing This API
          Ganciclovir 250 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Lecithin, soybean; Povidone; Cellulose, microcrystalline; Ferric oxide black; Gelatin; Shellac
                   Dosage Form Oral Capsule
                   Company Ranbaxy Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [2]
Povidone DIG Info Cholesterol 25-hydroxylase (IC50 = 78.3 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
Soybean lecithin DIG Info Albendazole monooxygenase (IC50 = 6.61 mg.mL-1) [5]
          Ganciclovir 500 mg capsule Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Fd&c blue no. 2; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Croscarmellose sodium; Lecithin, soybean; Povidone; Cellulose, microcrystalline; Ferric oxide black; Gelatin; Shellac
                   Dosage Form Oral Capsule
                   Company Ranbaxy Pharmaceuticals
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
FD&C blue no. 2 DIG Info Adenosine receptor A3 (IC50 = 1 uM) [2]
Povidone DIG Info Cholesterol 25-hydroxylase (IC50 = 78.3 uM) [3]
Magnesium stearate DIG Info Albendazole monooxygenase (Protein expression downregulation) [4]
Carmellose sodium DIG Info Albendazole monooxygenase (Protein expression upregulation) [4]
Soybean lecithin DIG Info Albendazole monooxygenase (IC50 = 6.61 mg.mL-1) [5]
          Ganciclovir Sodium eq 500mg base/vial injectable Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Hydrochloric Acid; Sodium Hydroxide
                   Dosage Form Injectable
                   Company Fresenius Kabi Usa ; H2-Pharma ; Pharmascience
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Hydrochloric acid DIG Info Carbonic anhydrase V (Ki = 156 nM) [6]
References
1 FDA label for approved ganciclovir from the official website of the U.S. Food and Drug Administration.
2 The activities of drug inactive ingredients on biological targets. Science. 2020 Jul 24;369(6502):403-413.
3 Mediation of in vitro cytochrome p450 activity by common pharmaceutical excipients. Mol Pharm. 2013 Jul 1;10(7):2739-48.
4 Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells. Pharm Res. 2010 Aug;27(8):1703-12.
5 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
6 Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1; 14(21):5435-9.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.